| Title |
Neuroimaging in Parkinson’s disease
|
|---|---|
| Published in |
Neurotherapeutics, April 2004
|
| DOI | 10.1602/neurorx.1.2.243 |
| Pubmed ID | |
| Authors |
David J. Brooks |
| Abstract |
In this review, the potential role of positron emission tomography and single photon emission computed tomography as biological markers for diagnosing and following the progression of Parkinson's disease (PD) is discussed. Their value for assessing the efficacy of putative neuroprotective agents in PD and for revealing the pharmacological changes underlying the symptomatology and complications of this disorder is also considered. It is concluded that in the future functional imaging will provide a valuable adjunct to clinical assessment when judging the efficacy of putative neuroprotective approaches to PD. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Thailand | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| Chile | 1 | 3% |
| Brazil | 1 | 3% |
| Unknown | 36 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 21% |
| Student > Bachelor | 8 | 21% |
| Other | 4 | 10% |
| Student > Master | 4 | 10% |
| Student > Postgraduate | 3 | 8% |
| Other | 10 | 26% |
| Unknown | 2 | 5% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 38% |
| Agricultural and Biological Sciences | 5 | 13% |
| Psychology | 5 | 13% |
| Neuroscience | 5 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Other | 3 | 8% |
| Unknown | 4 | 10% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2015.
All research outputs
#17,286,379
of 25,374,647 outputs
Outputs from Neurotherapeutics
#1,053
of 1,307 outputs
Outputs of similar age
#58,793
of 64,948 outputs
Outputs of similar age from Neurotherapeutics
#9
of 9 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,307 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 64,948 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one.